LIFR and oculocutaneous albinism: Our study identifies LIFR signaling as a critical vulnerability in Ras/Raf-mutant OCa, and LGSOC and demonstrates the therapeutic potential of targeting this pathway using the LIFR inhibitor EC359, both as a monotherapy and in combination with the MEK inhibitor trametinib.